EGFR and glioblastoma: CD40 agonist treatment in combination with D2C7-IT, a dual immunotoxin that targets specifically the human epidermal growth factor receptor (EGFR) and mutant EGFR variant III (vIIII) proteins, has also been reported to repolarize macrophages and boost their antitumoral immune response in GBM models increasing patient survival outcomes (176) (Figure 3).